|

Odronextamab Clinical Trials

8 actively recruiting trials across 6 locations

Also known as: Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody REGN1979, Ordspono, R1979, REGN-1979, REGN1979 +1 more

Pipeline

Phase 1: 1Phase 2: 3Phase 3: 3Phase 2/3: 1

Top Sponsors

  • Regeneron Pharmaceuticals4
  • University of Washington1
  • University of Birmingham1
  • Joseph Tuscano1
  • Gottfried von Keudell, MD PhD1

Indications

  • Cancer7
  • Refractory Diffuse Large B-Cell Lymphoma2
  • Recurrent Diffuse Large B-Cell Lymphoma2
  • Lupus Nephritis (LN)1
  • Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)1

Other2 trials

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Phase 2/3
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Phase 3

Tucson, Arizona1 trial

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

University of Arizona Cancer Center

Phase 3

Los Angeles, California1 trial

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

David Geffen School of Medicine at UCLA

Phase 3

Sacramento, California1 trial

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

University of California Davis Comprehensive Cancer Center

Phase 2

Boston, Massachusetts1 trial

Odronextamab in Low Tumor Volume Advanced FL

Beth Israel Deaconess Medical Center

Phase 2

Rochester, Minnesota1 trial

Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Mayo Clinic

Phase 1

Seattle, Washington1 trial

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.